SHSE:600594 (China)
Â
Class A
Â¥
3.41
-0.030 (-0.87%)
Apr 25
What is a stock summary page? Click here for an overview.
Business Description
Guizhou Yibai Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE000001H03
Share Class Description:
SHSE:600594: Class ACompare
Compare
Traded in other countries / regions
600594.China Index Membership
SSE Composite Index IPO Date
2004-03-23Description
Guizhou Yibai Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical products in China. Its products include tumor, cardio-cerebral vascular, respiratory system, anti-rheumatic, digestive system, pediatric, gynecological, andrological, anti-infection, anti-inflammatory, analgesic, tonic, and other drugs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.72 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.33 | |||||
| Debt-to-EBITDA | -4.16 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.18 | |||||
| Beneish M-Score | -3.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.1 | |||||
| 3-Year EBITDA Growth Rate | -9.4 | |||||
| 3-Year EPS without NRI Growth Rate | -29.1 | |||||
| 3-Year Book Growth Rate | -3.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.14 | |||||
| 9-Day RSI | 45.82 | |||||
| 14-Day RSI | 46.49 | |||||
| 3-1 Month Momentum % | 5.97 | |||||
| 6-1 Month Momentum % | -4.83 | |||||
| 12-1 Month Momentum % | -11.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2 | |||||
| Quick Ratio | 1.36 | |||||
| Cash Ratio | 0.71 | |||||
| Days Inventory | 249.31 | |||||
| Days Sales Outstanding | 31.35 | |||||
| Days Payable | 65.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.92 | |||||
| Forward Dividend Yield % | 1.92 | |||||
| 5-Year Yield-on-Cost % | 1.92 | |||||
| Shareholder Yield % | 6.83 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.25 | |||||
| Operating Margin % | -3.78 | |||||
| Net Margin % | -9.83 | |||||
| FCF Margin % | 5.76 | |||||
| ROE % | -8.25 | |||||
| ROA % | -5.21 | |||||
| ROIC % | -2.69 | |||||
| 3-Year ROIIC % | 38.51 | |||||
| ROC (Joel Greenblatt) % | -9.42 | |||||
| ROCE % | -5.86 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 56.83 | |||||
| PS Ratio | 1.12 | |||||
| PB Ratio | 1.02 | |||||
| Price-to-Tangible-Book | 1.25 | |||||
| Price-to-Free-Cash-Flow | 19.7 | |||||
| Price-to-Operating-Cash-Flow | 11.56 | |||||
| EV-to-EBIT | -14.9 | |||||
| EV-to-EBITDA | -14.9 | |||||
| EV-to-Revenue | 1.29 | |||||
| EV-to-FCF | 23.17 | |||||
| Price-to-GF-Value | 0.78 | |||||
| Price-to-Projected-FCF | 0.7 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Price-to-Net-Current-Asset-Value | 12.63 | |||||
| Earnings Yield (Greenblatt) % | -6.71 | |||||
| FCF Yield % | 5.11 | |||||
| Forward Rate of Return (Yacktman) % | 2.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guizhou Yibai Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,397.567 | ||
| EPS (TTM) (Â¥) | -0.298 | ||
| Beta | 1.19 | ||
| 3-Year Sharpe Ratio | -0.69 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 36.69 | ||
| 14-Day RSI | 46.49 | ||
| 14-Day ATR (Â¥) | 0.152363 | ||
| 20-Day SMA (Â¥) | 3.427 | ||
| 12-1 Month Momentum % | -11.47 | ||
| 52-Week Range (Â¥) | 2.76 - 4.53 | ||
| Shares Outstanding (Mil) | 791.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guizhou Yibai Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guizhou Yibai Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guizhou Yibai Pharmaceutical Co Ltd Frequently Asked Questions
What is Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594)'s stock price today?
The current price of SHSE:600594 is ¥3.41. The 52 week high of SHSE:600594 is ¥4.53 and 52 week low is ¥2.76.
When is next earnings date of Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594)?
The next earnings date of Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) is .
Does Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) pay dividends? If so, how much?
The Dividend Yield %  of Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) is 1.92% (As of Today), Highest Dividend Payout Ratio of Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) was 2.52. The lowest was 0.04. And the median was 0.21. The  Forward Dividend Yield % of Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) is 1.92%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers